HOME >> BIOLOGY >> NEWS
JCI Table of Contents, November 3, 2003

Gene therapy establishes a TRAIL to arthritis treatment

In the November 3 issue of the Journal of Clinical Investigation, John Mountz and colleagues from the University of Alabama at Birmingham describe a gene-modified cell therapy utilizing the TRAIL molecule that successfully limits the incidence and severity of arthritis in a mouse model of collagen-induced arthritis and joint inflammation. The regime represents a therapeutic option for systemic rheumatic diseases.

Mountz and colleagues isolated dendritic cells prepared from either peripheral blood or bone marrow, which were then pulsed with collagen. The DNA of an adenovirus expressing tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) was then introduced into these cells. The design of the adenovirus vector allowed the researchers to "switch on" the expression of TRAIL by these gene-modified dendritic cells at their discretion, by the addition of doxycycline (DOX).

A cascade of immunological events including lymphocyte activation, lymphokine production, and proliferation of synovial cells (which comprise the loose connective tissue lining the joint cavity) is associated with collagen-induced arthritis in mice. Mountz and colleagues found that infusion of collagen-pulsed DOX-inducible TRAIL-expressing dendritic cells into these mice induced the apoptosis of collagen-specific T cells, a reduction in lymphokine production, and suppression of collagen-induced arthritis. The data suggest that this gene therapy regime is a safe and effective method for inhibiting the development of collagen-induced arthritis

In an accompanying commentary in the same issue, George and Maria Tsokos from the Walter Reed Army Institute of Research, Maryland, discuss how the results of Mountz and colleagues propose new possibilities for gene-modified cellbased treatment of rheumatoid arthritis.

TITLE: CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
3-Nov-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, 1 October, 2003
4. JCI Table of Contents, September 15, 2003
5. JCI Table of Contents
6. JCI Table of Contents, 15 August 2003
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 19, 2020 , ... ... SalivaBio LLC, businesses dedicated to Salivary Bioscience for more than twenty years. Together ... book by Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva Research and Applications ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... in Princeton, NJ, have entered into license agreements with Housey Pharma’s HMI subsidiary ... Both Roche and J&J have annual Research and Development spending in excess of ...
(Date:8/7/2020)... , ... August 06, 2020 , ... ... participate in the prestigious National STEM Scholar Program, a unique professional development program ... and project support for middle school science teachers nationwide. , Created in partnership ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... TORONTO (PRWEB) , ... July 16, 2020 , ... After ... begins. The completion of a great surgery is only the beginning of a successful ... the research community. , Join Brad Gien, Global Head of Surgery from Envigo ...
(Date:7/10/2020)... ... July 09, 2020 , ... PathSensors Inc., ... has expanded the company’s exclusive license to include clinical applications for CANARY™ ... market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... date growth of 40% in 2020, despite many obstacles created as a result ... to increase revenue for its partnered medical practices and medical manufacturers by expanding ...
(Date:6/28/2020)... , ... June 25, 2020 , ... ... advance photodynamic therapy for treating cancer, today announced the company has entered a ... Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual ...
Breaking Biology Technology:
Cached News: